Addition of Post-Transplant Chemotherapy to Standard Immune Treatment Shows Increase of Allogeneic Transplant Patients in Remission

Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.

Read more